InsiderTrades.com logo
Claire Mazumdar net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Claire Mazumdar Biography and Net Worth

CEO of Bicara Therapeutics

The founding CEO of Bicara Therapeutics, Claire Mazumdar, led business development and corporate strategy at Rheos Medicines, where she supported a major partnership with Roche. As a Senior Associate at Third Rock Ventures, she focused on company formation and supported business development for TRV portfolio companies. She is also a Member of the Board of Directors for Noora Health, a global non-profit which works to improve patient outcomes and strengthen health systems by equipping family caregivers with the skills they need to care for their loved ones.

She holds a Bachelor of Science in Biological Engineering from MIT, earned her MBA from Stanford Graduate School of Business and a PhD in Cancer Biology from Stanford School of Medicine. Her research in tumor immunology and cancer epigenetics has been published in Nature, Cell Stem Cell and Cancer Cell.

What is Claire Mazumdar's net worth?

The estimated net worth of Claire Mazumdar is at least $7.08 million as of March 20th, 2026. Mazumdar owns 339,392 shares of Bicara Therapeutics stock worth more than $7,076,323 as of April 6th. This net worth approximation does not reflect any other assets that Mazumdar may own. Learn More about Claire Mazumdar's net worth.

How do I contact Claire Mazumdar?

The corporate mailing address for Mazumdar and other Bicara Therapeutics executives is 116 Huntington Avenue, Suite 703, Boston, MA 02116, United States. Bicara Therapeutics can also be reached via phone at (617) 468-4219 and via email at [email protected]. Learn More on Claire Mazumdar's contact information.

Has Claire Mazumdar been buying or selling shares of Bicara Therapeutics?

Claire Mazumdar has not been actively trading shares of Bicara Therapeutics during the last ninety days. Most recently, Claire Mazumdar sold 1,596 shares of the business's stock in a transaction on Friday, March 20th. The shares were sold at an average price of $18.95, for a transaction totalling $30,244.20. Following the completion of the sale, the chief executive officer now directly owns 339,392 shares of the company's stock, valued at $6,431,478.40. Learn More on Claire Mazumdar's trading history.

Who are Bicara Therapeutics' active insiders?

Bicara Therapeutics' insider roster includes Ryan Cohlhepp (COO), Ivan Hyep (CFO), Claire Mazumdar (CEO), and David Raben (Insider). Learn More on Bicara Therapeutics' active insiders.

Are insiders buying or selling shares of Bicara Therapeutics?

In the last year, insiders at the sold shares 33 times. They sold a total of 374,566 shares worth more than $6,946,222.67. The most recent insider tranaction occured on March, 23rd when CFO Ivan Hyep sold 9,200 shares worth more than $170,384.00. Insiders at Bicara Therapeutics own 15.5% of the company. Learn More about insider trades at Bicara Therapeutics.

Information on this page was last updated on 3/23/2026.

Claire Mazumdar Insider Trading History at Bicara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2026Sell1,596$18.95$30,244.20339,392View SEC Filing Icon  
3/19/2026Sell6,905$18.78$129,675.90339,392View SEC Filing Icon  
3/18/2026Sell6,499$18.84$122,441.16339,392View SEC Filing Icon  
3/9/2026Sell36,766$19.17$704,804.22339,392View SEC Filing Icon  
3/6/2026Sell3,817$18.75$71,568.75339,392View SEC Filing Icon  
3/5/2026Sell1,786$18.74$33,469.64339,392View SEC Filing Icon  
3/4/2026Sell2,631$18.73$49,278.63339,392View SEC Filing Icon  
11/24/2025Sell41,163$18.86$776,334.18309,892View SEC Filing Icon  
10/15/2025Sell13,289$18.84$250,364.76309,892View SEC Filing Icon  
10/13/2025Sell11,445$18.92$216,539.40309,892View SEC Filing Icon  
See Full Table

Claire Mazumdar Buying and Selling Activity at Bicara Therapeutics

This chart shows Claire Mazumdar's buying and selling at Bicara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bicara Therapeutics Company Overview

Bicara Therapeutics logo
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $20.85
Low: $20.62
High: $21.63

50 Day Range

MA: $17.55
Low: $14.06
High: $21.47

2 Week Range

Now: $20.85
Low: $7.80
High: $21.63

Volume

552,051 shs

Average Volume

615,416 shs

Market Capitalization

$1.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A